Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068114 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL1131364 | 0.90 | SRC (0.42) | SMN1; SMN2ALDH1A1SRC | |
| SCHEMBL8026613 | 0.84 | ELANE (0.48) | HSD17B10SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL1131373 | 0.83 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1SRC | |
| SCHEMBL10255074 | 0.83 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1SRC | |
| SCHEMBL29255152 | 0.81 | LTA4H (0.49) | LTA4HABL1BCR | |
| SCHEMBL3892192 | 0.78 | ABL1 (0.37) | SMN1; SMN2GPR119SRCABL1BCR | |
| SCHEMBL8025306 | 0.77 | ELANE (0.46) | HSD17B10SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL13898314 | 0.76 | MAPT (0.51) | ALDH1A1GPR119MEN1KMT2A | |
| SCHEMBL1371585 | 0.75 | HTRA1 (0.48) | SMN1; SMN2ALDH1A1HPGDMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694086-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-25 | — | — | US | disclosed |
| US-20160235805-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-18 | — | — | US | disclosed |
| US-9163061-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8309685-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| WO-2011002807-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-2237667-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082697-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235805-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885SMN1; SMN2 4140/4885ALDH1A1 1344/4885 |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885SMN1; SMN2 4140/4885ALDH1A1 1344/4885 |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885SMN1; SMN2 4140/4885ALDH1A1 1344/4885 |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885SMN1; SMN2 4140/4885ALDH1A1 1344/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HSD17B10 877/4885SMN1; SMN2 4140/4885ALDH1A1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.